Adaptimmune Therapeutics Intrinsic Value – Comparing the Potential of Axcella Health and Adaptimmune Therapeutics in the Biotech Industry
April 8, 2023
Trending News 🌥️
Adaptimmune’s lead product candidate is its NY-ESO TCR (T-cell receptor), which is designed to target and attack multiple types of cancer. The company is currently conducting clinical trials of the NY-ESO TCR in patients with solid tumors and is currently exploring other therapeutic approaches. At the same time, Axcella Health is a biopharmaceutical company based in Cambridge, Massachusetts. Axcella is also developing novel therapeutics to treat liver diseases, such as NASH and PBC, as well as other metabolic health disorders. In a comparison between Axcella Health and Adaptimmune Therapeutics ($NASDAQ:ADAP), it is clear that both companies have unique approaches to addressing different illnesses. While Adaptimmune focuses on developing T-cell therapy for cancer, Axcella focuses on treating metabolic health disorders. As such, both companies have their respective strengths and weaknesses and will be competing for the same markets.
However, it is worth noting that Adaptimmune’s current clinical trial of the NY-ESO TCR is showing promising results and could potentially be a much needed breakthrough in treating solid tumor cancers. In conclusion, while both companies have potential in the biotech industry, it appears that Adaptimmune has a slight edge due to its more advanced development of its T-cell therapy.
Market Price
Adaptimmune Therapeutics is a biotechnology company specializing in the development of innovative cancer immunotherapies. The stock market tends to react differently to news of individual companies, which can cause their performance to vary greatly when compared to one another. This difference in performance could be due to any number of factors such as news from the companies, industry trends, or analyst opinions. Investors interested in either company should continue to monitor their stock performance as well as news related to their respective industries. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Adaptimmune Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 27.15 | -165.46 | -604.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Adaptimmune Therapeutics. More…
| Operations | Investing | Financing |
| -141.77 | 89.14 | 12.87 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Adaptimmune Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 328.92 | 247.04 | 0.5 |
Key Ratios Snapshot
Some of the financial key ratios for Adaptimmune Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 189.2% | – | -595.5% |
| FCF Margin | ROE | ROA |
| -631.8% | -103.5% | -30.7% |
Analysis – Adaptimmune Therapeutics Intrinsic Value
At GoodWhale, we have analyzed the wellbeing of ADAPTIMMUNE THERAPEUTICS, and our proprietary Valuation Line tells us that its fair value is around $20.6. Currently, the stock is only trading at $1.1, which represents an undervaluation of 94.7%! This presents an exceptional opportunity for investors to make a significant return on their investment. More…
Peers
The company’s T-cell therapy platform harnesses the body’s own immune system to target and kill cancer cells. Adaptimmune’s lead product candidate, ADAPT-101, is in clinical trials for the treatment of solid tumors. The company is also developing product candidates for the treatment of blood cancers. Adaptimmune’s main competitors are Iovance Biotherapeutics Inc, TCR2 Therapeutics Inc, and Adicet Bio Inc. All three companies are developing T-cell therapies for the treatment of cancer.
– Iovance Biotherapeutics Inc ($NASDAQ:IOVA)
Iovance Biotherapeutics Inc is a biopharmaceutical company that focuses on the development and commercialization of cancer immunotherapy products. The company has a market cap of 1.24B as of 2022 and a Return on Equity of -56.45%. The company’s products are based on its proprietary technology platform, which harnesses the power of the body’s immune system to recognize and kill cancer cells. Iovance Biotherapeutics Inc’s products are in clinical and commercial development stages for the treatment of various solid tumor types.
– TCR2 Therapeutics Inc ($NASDAQ:TCRR)
The company’s market cap is 49.48 million as of 2022, a return on equity of -24.78%. The company is focused on the development of immunotherapies for the treatment of cancer.
– Adicet Bio Inc ($NASDAQ:ACET)
Adicet Bio Inc is a clinical stage biopharmaceutical company focused on developing next-generation cell therapies for cancer and other intractable diseases. The company’s lead product candidate, ADI-001, is a universal donor platform cell therapy using allogeneic, or donor-derived, gamma delta T cells that can be used to treat any patient, without the need for human leukocyte antigen (HLA) matching. The company is also developing ADI-002, a natural killer cell therapy platform for the treatment of solid tumors.
Adicet Bio Inc has a market cap of 836.46M as of 2022, a Return on Equity of -9.85%. Adicet Bio is a clinical stage biopharmaceutical company focused on developing next-generation cell therapies for cancer and other intractable diseases. The company’s lead product candidate, ADI-001, is a universal donor platform cell therapy using allogeneic, or donor-derived, gamma delta T cells that can be used to treat any patient, without the need for human leukocyte antigen (HLA) matching. The company is also developing ADI-002, a natural killer cell therapy platform for the treatment of solid tumors.
Summary
Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The company’s lead product candidates are affinity engineered T-cell receptors (TCRs) and specific T-cell therapies targeting solid tumors and hematological malignancies. The TCR technology is based on the company’s proprietary affinity enhanced T-cell receptor platform, which is designed to enable the recognition of cancer antigens and activate the patient’s own immune system to target and eliminate cancer cells. Adaptimmune Therapeutics has demonstrated promising clinical results, with Phase I/II clinical trials showing the potential for efficacy in multiple indications. The company has strong patents and intellectual property protections, and its products are expected to be cost-effective compared to other cancer treatments.
Additionally, the company has aligned itself with strategic partnerships that have enabled its growth and expansion, making Adaptimmune Therapeutics an attractive option for investors.
